8-K: Genprex Secures $3.4M Upfront in Direct Offering

Genprex, Inc. announced a registered direct offering of common stock and concurrent private placement of warrants, expecting $3.4 million upfront and up to $6.6 million from warrant exercises.

Summary

• Genprex, Inc. entered into a securities purchase agreement on October 28, 2025, for a registered direct offering and concurrent private placement.
• The registered direct offering involves the sale of 377,780 shares of common stock at a purchase price of $9.00 per share.
• The concurrent private placement includes warrants exercisable for up to 755,560 shares of common stock.
• The private warrants have an exercise price of $8.75 per share and will expire 24 months from the effective date of a resale registration statement.
• The offering is expected to close on or about October 29, 2025.
• Net proceeds from the registered direct offering, after deducting placement agent fees and other estimated expenses, are expected to be approximately $3.0 million.
• Potential additional gross proceeds from the full exercise of the private warrants are approximately $6.6 million, though no assurance is given for their exercise.
• The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
• H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a cash fee equal to 7.0% of gross proceeds and a management fee equal to 1.0% of gross proceeds, plus expense reimbursements.
• The company also issued Placement Agent Warrants to purchase up to 22,667 shares of common stock (6.0% of shares sold) with an exercise price of $11.25 per share and a termination date of the earlier of 24 months from resale registration effectiveness or October 28, 2030.
• Purchasers from a prior October 23, 2025 offering waived certain restrictions on the company issuing common stock and equivalents to facilitate this new offering.

Sentiment

Score: 5

Explanation: The offering provides necessary capital for working capital and general corporate purposes, which is positive for a clinical-stage company. However, it comes with significant dilution and fees, and the additional capital from warrants is not guaranteed, leading to a neutral to slightly positive sentiment.

Positives

• Secured approximately $3.0 million in net proceeds from the registered direct offering, providing immediate capital.
• Potential to raise an additional $6.6 million if all private warrants are exercised, offering future funding flexibility.
• Funds are designated for working capital and general corporate purposes, supporting ongoing operations and strategic initiatives.
• Waiver of prior offering restrictions allowed for this new capital raise, demonstrating flexibility in financing strategies.

Negatives

• Issuance of 377,780 shares of common stock and warrants for up to 755,560 shares will result in significant dilution for existing shareholders.
• Substantial fees and expenses are payable to the placement agent, including a 7.0% cash fee, a 1.0% management fee, expense reimbursements, and Placement Agent Warrants.
• The exercise price of the private warrants ($8.75) is below the offering price of the common stock ($9.00), indicating a discount for warrant holders.
• The company agreed to a 5-day lock-up on issuing new equity and a 12-month prohibition on variable rate transactions, with certain exceptions, which could limit future financing options.

Risks

• No assurance that the short-term warrants will be exercised for cash or at all, meaning the potential additional $6.6 million is not guaranteed.
• Forward-looking statements involve risks and uncertainties, including the company's financial position and market conditions, which could cause actual results to differ materially.
• Past or future open market or other transactions by purchasers, including short sales or derivative transactions, may negatively impact the market price of the company's publicly-traded securities.
• Hedging activities by purchasers could reduce the value of existing shareholders' equity interests in the company.
• Warrant Shares acquired upon exercise, if not registered and if cashless exercise is not utilized, will have resale restrictions imposed by state, federal, or foreign securities laws.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. It also plans to file a registration statement on Form S-1 for the resale of Private Warrant Shares within 30 calendar days and use commercially reasonable efforts to make it effective within 60-90 days. The company cautions that forward-looking statements involve risks and uncertainties, and there is no assurance that warrants will be exercised.

Management Comments

• The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Industry Context

This capital raise provides Genprex, a clinical-stage gene therapy company, with additional funding for its operations, which is crucial for companies in the biotechnology sector that typically require substantial capital for research, development, and clinical trials. The use of a registered direct offering combined with a private placement of warrants is a common financing strategy for smaller public companies to raise capital efficiently while offering incentives to investors.

Stakeholder Impact

• Shareholders: Experience immediate dilution from the issuance of new common stock and potential future dilution from the exercise of warrants. The capital raise provides funding for ongoing operations, which could support long-term value if successful.
• Investors (Purchasers): Acquire common stock at $9.00 per share and warrants at an exercise price of $8.75, offering potential upside. They also benefit from registration rights for warrant shares.
• Company Operations: Receives capital for working capital and general corporate purposes, enabling continued development of gene therapies for cancer and diabetes.
• Placement Agent (H.C. Wainwright & Co.): Earns substantial fees (cash and warrants) for facilitating the offering.

Next Steps

• Closing of the offering is expected on or about October 29, 2025.
• The company will file a registration statement on Form S-1 for the resale of Private Warrant Shares within 30 calendar days of the Purchase Agreement date.
• The company will use commercially reasonable efforts to cause the S-1 registration statement to become effective within 60 calendar days (or 90 days if full SEC review).
• The company will keep the resale registration statement effective until no Purchaser owns Warrants or Warrant Shares.
• The company agrees to maintain the listing or quotation of its Common Stock on the Trading Market and apply to list all Shares and Warrant Shares on such market.

Key Dates

Recommendation

While the capital raise provides necessary funding for Genprex's clinical-stage operations, the significant dilution from the shares and warrants, coupled with substantial placement agent fees, offsets the immediate benefit. The uncertainty of warrant exercise for additional capital and the 12-month restriction on variable rate transactions (with exceptions) suggest a cautious 'hold' stance. Investors should monitor the company's progress in clinical trials and the actual exercise of warrants for future upside potential.

Keywords

Genprex, GNPX, Registered Direct Offering, Private Placement, Common Stock, Warrants, Equity Financing, Capital Raise, SEC Filing, Biotechnology, Gene Therapy, Oncology, Diabetes, H.C. Wainwright